美国心力衰竭管理系统的成本效益分析
Antonia Bosworth Smith1, Ubong Silas1, Alex Veloz2
1Coreva Scientific GmbH & Co. KG, Königswinter, Germany.
Journal of health economics and outcomes research
|March 20, 2025
概括
心力衰竭管理系统 (HFMS) 是一个具有成本效益的解决方案,与标准护理相比,可降低心力衰竭患者的再入院和医疗保健成本. 这种新的监控设备在五年内可以节省大量资金并改善结果.
科学领域:
- 心血管医学 心血管医学
- 卫生经济学 卫生经济学
- 医疗技术 医疗技术 医学技术
背景情况:
- 心力衰竭造成了严重的疾病负担,主要是由于高的再入院率.
- 远程监控设备有可能在出院后的心力衰竭患者中早期检测恶化的症状.
- 心脏衰竭管理系统 (HFMS) 是一种新的设备,有望防止重入院.
研究的目的:
- 评估心脏衰竭管理系统 (HFMS) 与美国标准护理 (SOC) 的成本效益.
- 分析HFMS在5年的经济影响和临床结果.
主要方法:
- 马尔科夫模型被用来模拟心力衰竭住院后出院后的患者途径.
- 该模型从付款人的角度考虑了成本,医院再入院和潜在的护理升级.
- 经济终点使用增量成本效益比率 (ICER) 来衡量,支付意愿的门为每次避免重返入境的10737美元.
主要成果:
- 高水系统展示了一个主导策略,将平均5年成本从161,846美元 (SOC) 降低到155,122.2美元.
- 随着HFMS,医院再入院的病例从1.201个事件减少到1.075个事件 (每名患者减少0.126个事件).
- 使用HFMS的成本节约开始于释放后的第三个月,93.4%的模拟显示成本和再接收减少.
结论:
- 心力衰竭管理系统 (HFMS) 是一种具有成本效益的干预措施,用于治疗心力衰竭患者退院后.
- 与标准护理相比,HFMS显著降低了医疗保健支出和医院再入院率.
- 建议进行进一步的长期研究,以验证这些基于模型的研究结果对HFMS的影响.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
01:22Heart Failure Drugs: Diuretics
312
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
312
01:26Heart Failure Drugs: Inotropic Agents
479
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
479
01:15Methods of Documentation VI: Case Management Model
556
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
556